Researcher
Hannelore Denys
- Keywords:Clinical trials, Fundamental and translational research, Uterine cancer, cervical cancer, Breast cancer, Ovarian cancer
- Disciplines:Cancer diagnosis, Cancer epidemiology, Oncology not elsewhere classified, Cancer therapy, Cancer biology
Affiliations
- Board of Governors/Executive Board (Administrative office)
Member
From1 Oct 2022 → Today - Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Internal medicine (Department)
Member
From1 Oct 2011 → 30 Sep 2018
Projects
1 - 10 of 11
- Chitinase 3-like 1 as novel immunotherapeutic target in triple-negative breast cancerFrom1 Oct 2021 → TodayFunding: FWO junior postdoctoral fellowship
- PRIMMO trial - Extracellular vesicles to predict response to checkpoint inhibitors in cervical and endometrial cancer patientsFrom1 Jan 2021 → 31 Dec 2021Funding: Nonprofit institution or equivalents
- Analyzing circulating bacterial extracellular vesicles in cancer patients to identify their composition and biomarker potential.From1 Nov 2020 → 31 Mar 2023Funding: FWO fellowships
- Preclinical validation of novel anti-EMT therapy for malignant triple negative breast cancerFrom1 Mar 2020 → TodayFunding: Nonprofit institution or equivalents
- EV-TRACE: Extracellular Vesicle Tracking using surface proteins and Resonance Assays to detect breast Cancer in Early stageFrom1 Jan 2020 → 31 Dec 2023Funding: FWO Strategic Basic Research (SBO)
- Heading towards an in vivo predictive test for personalized ovarian cancer treatment: application of novel therapies in zebrafish patient derived xenograftsFrom1 Nov 2019 → TodayFunding: FWO Strategic Basic Research Grant
- Impact of vaginal morbidity on sexual functioning in cervical cancer patients treated with neo-adjuvant chemotherapy followed by surgery.From1 Jan 2019 → 31 Dec 2020Funding: FWO research project (including WEAVE projects)
- beurs EVDS Sofie Van Dorpe: Extracellular vesicles as blood-based biomarker for early stage ovarian cancerFrom1 Oct 2018 → 30 Sep 2019Funding: Foundations, funds and other with scientific goal
- Targeting cancer-associated fibroblasts to overcome immunosuppressive mechanisms in mismatch repair-deficient tumorsFrom1 Oct 2018 → 30 Sep 2022Funding: FWO fellowships
- Combination of radiotherapy, PD-1 blockade and an immune-modulatory cocktail to combat cervical and uterine cancerFrom1 Jan 2017 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
Publications
61 - 70 of 125
- Multicenter cross-sectional study comparing quality of life, body image after breast cancer surgery(2013)Volume: 22
Authors: Daan De Maeseneer, MICHIEL STRIJBOS, Phillip Blondeel, Rudy Van den Broecke, Herman Depypere, Geert Braems, Hannelore Denys, Simon Van Belle, Veronique Cocquyt
Pages: S76 - S76 - Evaluation of the quality of the management of cancer of the corpus uteri: selection of relevant quality indicators and implementation in Belgium(2013)
Authors: J Werbrouck, G Bouche, E de Jonge, G Jacomen, V D'Hondt, Hannelore Denys, E Van Limbergen, B Vandermeersch, H De Schutter, E Van Eycken, et al.
Pages: 512 - 519 - Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling(2013)
Authors: Astrid De Boeck, Patrick Pauwels, Karen Hensen, Jean-Luc Rummens, Wendy Westbroek, An Hendrix, Dawn Maynard, Hannelore Denys, Kathleen Lambein, Christian Gespach, et al.
Pages: 550 - 560 - Vacuolar H+ ATPase expression and activity is required for Rab27B dependent invasive growth and metastasis of breast cancer(2013)
Authors: An Hendrix, Raija Sormunen, Wendy Westbroek, Kathleen Lambein, Hannelore Denys, Gwen Sys, Rudy Van den Broecke, Veronique Cocquyt, Christian Gespach, Marc Bracke
Pages: 843 - 854 - Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast(2013)
Authors: Mieke Van Bockstal, Kathleen Lambein, Olivier Gevaert, Marleen Praet, Veronique Cocquyt, Rudy Van den Broecke, Hannelore Denys, Louis Libbrecht
Pages: 520 - 533 - Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance(2013)
Authors: Kathleen Lambein, Mieke Van Bockstal, LIES VANDEMAELE, SOFIE GEENEN, Isabelle Rottiers, ANN NUYTS, BART MATTHYS, Marleen Praet, Hannelore Denys, Louis Libbrecht
Pages: 561 - 566 - Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer(2012)
Authors: Wim Ceelen, Simon Van Belle, Hannelore Denys
Pages: 2352 - 2359 - Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations(2011)
Authors: Kathleen Lambein, Marleen Praet, Ramses Forsyth, Rudy Van den Broecke, BART MATTHYS, Veronique Cocquyt, Hannelore Denys, Patrick Pauwels, Louis Libbrecht
Pages: 200 - 207 - Adipose tissue in breast cancer : not an idle bystander but an active participant in breast cancer progression(2011)Volume: 71
Authors: An Hendrix, Kathleen Lambein, P Valet, Rudy Van den Broecke, Marc Bracke, Veronique Cocquyt, Hannelore Denys
Number of pages: 1 - The secretory GTPase RAB27b drives poor prognosis in ER alpha-positive breast cancer(2010)Volume: 21
Authors: An Hendrix, Hannelore Denys, Geert Braems, Patrick Pauwels, Rudy Van den Broecke, Veronique Cocquyt, Wendy Westbroek, Marc Bracke, Olivier De Wever
Pages: 53 - 53